Assessing Clinical Outcomes in Alzheimer's Disease Agitation

Summary

This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjects with agitation associated with Alzheimer's disease.

Timeline

Start

2020-12-31

Primary completion

2022-11-21

Completion

2022-11-21

Drugs

Indications